医疗技术公司TransMedics Group Inc.(TMDX.US)在2024年10月28日晚间暴跌近25%,令投资者失望。此前,该公司公布的2024年第三季度财报数据低于市场预期,令人对其未来增长前景产生质疑。
根据财报显示,TransMedics Group第三季度营收为1.088亿美元,远低于华尔街分析师平均预期的1.15亿美元。净利润仅为每股12美分,同样未能达到预期的每股29美分。尽管公司维持了全年营收在4.25亿至4.45亿美元的指引,但投资者显然对其业绩增长表示失望。
TransMedics Group是一家专注于为终末期器官衰竭患者提供移植治疗的医疗技术公司。财报数据暴露出公司在某些领域可能面临增长瓶颈,无法继续保持之前的高速增长势头。这使得其股价在盘后出现重挫,跌幅高达28.87%,报收于90.20美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.